The Department of Defense (DoD) offers the Amyotrophic Lateral Sclerosis Therapeutic Idea Award to fund innovative research ideas focused on drug, treatment, and target discovery in the early stages of development to advance ALS treatment. Projects should have a strong scientific rationale with translational potential. For the FY15 award, topics include high-throughput screens for target identification and preclinical model system development. Emphasis is on innovation and impact, with a focus on new ideas rather than preliminary data. Applicants seeking advanced preclinical development should apply for the Therapeutic Development Award. Deadline for submission is Aug 20, 2015.
Opportunity ID: 275280
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-15-ALSRP-TIA |
| Funding Opportunity Title: | DoD Amyotrophic Lateral Sclerosis Therapeutic Idea Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 4 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Mar 18, 2015 |
| Last Updated Date: | Mar 30, 2015 |
| Original Closing Date for Applications: | Aug 20, 2015 |
| Current Closing Date for Applications: | Aug 20, 2015 |
| Archive Date: | Sep 19, 2015 |
| Estimated Total Program Funding: | $3,200,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The Therapeutic Idea Award is designed to promote new ideas aimed at drug, treatment, and target discovery that are still in the early stages of development. Proposed research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality. Projects that focus primarily on investigating the pathophysiology of ALS are outside the scope of this mechanism.New for FY15: In addition to hypothesis-based ideas aimed at drug or treatment discovery, the FY15 Therapeutic Idea Award will support the following topics, which were previously supported under the ALSRP Therapeutic Development Award mechanism. Development, validation, and application of high-throughput screens to define targets with therapeutic potential or to identify lead agent candidates for ALS treatment; Development, modification, and/or validation of preclinical model systems in order to assess lead compounds and potential therapeutics by pharmacological and/or pharmacokinetic testing. Such models would also serve as improved tools for the ALS research community.Applicants contemplating development of products beyond drug or treatment discovery should apply to the ALSRP Therapeutic Development Award, which supports advanced preclinical development activities.Innovation and impact are the most important aspects of the Therapeutic Idea Award. Applications that demonstrate exceptional scientific merit but lack innovation and highDoD FY15 ALSRP Therapeutic Idea Award 4potential impact do not meet the intent of the Therapeutic Idea Award. Presentation of preliminary data is not consistent with the intent of the Therapeutic Idea Award mechanism. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative idea and the potential impact it will provide. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email:Email: help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Section IV ADMINISTRATIVE ACTIONS, A. Rejection has been amended to include: “Project Narrative exceeds page limit. “ |
Mar 30, 2015 | |
| Section IV ADMINISTRATIVE ACTIONS, A. Rejection has been amended to include: “Project Narrative exceeds page limit. “ |
Mar 30, 2015 | |
| Mar 30, 2015 |
DISPLAYING: Synopsis 3
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-15-ALSRP-TIA |
| Funding Opportunity Title: | DoD Amyotrophic Lateral Sclerosis Therapeutic Idea Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 4 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Mar 18, 2015 |
| Last Updated Date: | Mar 30, 2015 |
| Original Closing Date for Applications: | Aug 20, 2015 |
| Current Closing Date for Applications: | Aug 20, 2015 |
| Archive Date: | Sep 19, 2015 |
| Estimated Total Program Funding: | $3,200,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The Therapeutic Idea Award is designed to promote new ideas aimed at drug, treatment, and target discovery that are still in the early stages of development. Proposed research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality. Projects that focus primarily on investigating the pathophysiology of ALS are outside the scope of this mechanism.New for FY15: In addition to hypothesis-based ideas aimed at drug or treatment discovery, the FY15 Therapeutic Idea Award will support the following topics, which were previously supported under the ALSRP Therapeutic Development Award mechanism. Development, validation, and application of high-throughput screens to define targets with therapeutic potential or to identify lead agent candidates for ALS treatment; Development, modification, and/or validation of preclinical model systems in order to assess lead compounds and potential therapeutics by pharmacological and/or pharmacokinetic testing. Such models would also serve as improved tools for the ALS research community.Applicants contemplating development of products beyond drug or treatment discovery should apply to the ALSRP Therapeutic Development Award, which supports advanced preclinical development activities.Innovation and impact are the most important aspects of the Therapeutic Idea Award. Applications that demonstrate exceptional scientific merit but lack innovation and highDoD FY15 ALSRP Therapeutic Idea Award 4potential impact do not meet the intent of the Therapeutic Idea Award. Presentation of preliminary data is not consistent with the intent of the Therapeutic Idea Award mechanism. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative idea and the potential impact it will provide. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email:Email: help@eBRAP.org |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-15-ALSRP-TIA |
| Funding Opportunity Title: | DoD Amyotrophic Lateral Sclerosis Therapeutic Idea Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 4 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Mar 30, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Aug 20, 2015 |
| Archive Date: | Sep 19, 2015 |
| Estimated Total Program Funding: | $3,200,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The Therapeutic Idea Award is designed to promote new ideas aimed at drug, treatment, and target discovery that are still in the early stages of development. Proposed research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality. Projects that focus primarily on investigating the pathophysiology of ALS are outside the scope of this mechanism. New for FY15: In addition to hypothesis-based ideas aimed at drug or treatment discovery, the FY15 Therapeutic Idea Award will support the following topics, which were previously supported under the ALSRP Therapeutic Development Award mechanism. Development, validation, and application of high-throughput screens to define targets with therapeutic potential or to identify lead agent candidates for ALS treatment; Development, modification, and/or validation of preclinical model systems in order to assess lead compounds and potential therapeutics by pharmacological and/or pharmacokinetic testing. Such models would also serve as improved tools for the ALS research community. Applicants contemplating development of products beyond drug or treatment discovery should apply to the ALSRP Therapeutic Development Award, which supports advanced preclinical development activities. Innovation and impact are the most important aspects of the Therapeutic Idea Award. Applications that demonstrate exceptional scientific merit but lack innovation and high DoD FY15 ALSRP Therapeutic Idea Award 4 potential impact do not meet the intent of the Therapeutic Idea Award. Presentation of preliminary data is not consistent with the intent of the Therapeutic Idea Award mechanism. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative idea and the potential impact it will provide. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email:Email: help@eBRAP.org |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-15-ALSRP-TIA |
| Funding Opportunity Title: | DoD Amyotrophic Lateral Sclerosis Therapeutic Idea Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 4 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 30, 2015 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Aug 20, 2015 |
| Archive Date: | Sep 19, 2015 |
| Estimated Total Program Funding: | $3,200,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The Therapeutic Idea Award is designed to promote new ideas aimed at drug, treatment, and target discovery that are still in the early stages of development. Proposed research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality. Projects that focus primarily on investigating the pathophysiology of ALS are outside the scope of this mechanism. New for FY15: In addition to hypothesis-based ideas aimed at drug or treatment discovery, the FY15 Therapeutic Idea Award will support the following topics, which were previously supported under the ALSRP Therapeutic Development Award mechanism. Development, validation, and application of high-throughput screens to define targets with therapeutic potential or to identify lead agent candidates for ALS treatment; Development, modification, and/or validation of preclinical model systems in order to assess lead compounds and potential therapeutics by pharmacological and/or pharmacokinetic testing. Such models would also serve as improved tools for the ALS research community. Applicants contemplating development of products beyond drug or treatment discovery should apply to the ALSRP Therapeutic Development Award, which supports advanced preclinical development activities. Innovation and impact are the most important aspects of the Therapeutic Idea Award. Applications that demonstrate exceptional scientific merit but lack innovation and high DoD FY15 ALSRP Therapeutic Idea Award 4 potential impact do not meet the intent of the Therapeutic Idea Award. Presentation of preliminary data is not consistent with the intent of the Therapeutic Idea Award mechanism. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative idea and the potential impact it will provide. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email:Email: help@eBRAP.org |
Related Documents
Folder 275280 Full Announcement-1 -> alsrp_fy15 tia pa.3_gg.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00215656 | Mar 18, 2015 | Aug 20, 2015 | View |
Package 1
Mandatory forms
275280 RR_SF424_2_0-2.0.pdf
275280 RR_Budget_1_3-1.3.pdf
275280 RR_KeyPersonExpanded_2_0-2.0.pdf
275280 PerformanceSite_2_0-2.0.pdf
Optional forms
275280 RR_SubawardBudget30_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
